Printer Friendly

TECHNICLONE INTERNATIONAL CORPORATION ANNOUNCES THAT U.S. PATENT NO. 5,194,594 "MODIFIED ANTIBODIES" HAS BEEN ISSUED

 TUSTIN, Calif., July 9 /PRNewswire/ -- Techniclone International ("TCLN") announced today that it has been issued U.S. Patent No. 5,194,594, "Modified Antibodies." This invention chemically modifies the physiochemical properties of antibodies thereby creating an antibody with superior uptake in tumors and increased blood clearance times. These Modified Antibodies produce a 2 to 3 fold increase in tumor uptake, exhibit clearance profiles similar to F(ab')2 fragments and cause less toxicity than conventional antibodies and antibody fragments. When combined with company's other technologies, the new Modified Antibodies can treat a wide range of human cancers. The effect of the new Modified Antibodies technology has been demonstrated with several antibody models, and Lon Stone stated that he believes "that it is likely that Techniclone's patented approach will significantly improve both the diagnostic imaging and the therapeutic capabilities of monoclonal antibodies."
 Techniclone International is developing therapeutic monoclonal antibody technology for the treatment of cancer. Techniclone owns several novel inventions that overcome many of the obstacles previously encountered in attempts in the use of monoclonal antibodies in the treatment of solid tumors.
 -0- 7/9/93
 /CONTACT: Lon H. Stone, chairman and CEO of Techniclone International Corporation, 714-838-0500/


CO: Techniclone International ST: California IN: MCT SU:

TM -- NY004 -- 9756 07/09/93 07:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 9, 1993
Words:214
Previous Article:RLI SUBSIDIARY AWARDED UPGRADED RATING FROM A.M. BEST COMPANY; MT. HAWLEY INSURANCE COMPANY NOW RATED "A"
Next Article:PSE&G SETS NEW ELECTRIC PEAK DEMAND RECORD
Topics:


Related Articles
EUROPEAN PATENT OFFICE ALLOWS TECHNICLONE PATENT APPLICATION
TECHNICLONE INTERNATIONAL CORP. ANNOUNCES GRANT OF EUROPEAN PATENT
PROTEIN ENGINEERING CORP. RECEIVES BROAD U.S. COMPOSITION OF MATTER PATENT COVERING PHAGE DISPLAY FOR GENERATING MOLECULAR DIVERSITY
CELL GENESYS ISSUED TWO PATENTS FOR UNIVERSAL DONOR CELL TECHNOLOGY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters